Medical Necessity Justification



Patient/Member InformationPatient Name: DOB:Payor: Plan: Subscriber Name:DOBSubscriber Number:Provider/Contact InformationOrdering Provider:Contact Person:Phone:Fax:Genetic Test InformationName of test: Epilepsy Panel (89 genes)Test Code: 03402CPT code(s): 81479ICD10 code(s):List price:Do you have a preferred clinical laboratory for genetic testing? __ NO (or not applicable) X YES, (provide preferred lab name): InvitaePlease state the reason why testing should/must be performed at this laboratory: Clinical Reasoning for Genetic Test (Attach the clinic note)*** is a *** yo with a history of ***. -What laboratory and/or clinical testing have been performed to date (genetic and other testing)?-Why is genetic testing necessary at this time? Epilepsy is a group of disorders caused by disturbances with electrical signaling in the brain. Epilepsy may present as an isolated finding or as part of a broader phenotype. Several syndromic neurodevelopmental disorders include epilepsy as a prominent feature. Furthermore, several phenotypic subgroups of epilepsy exist. PFJlZm1hbj48Q2l0ZT48QXV0aG9yPk90dG1hbjwvQXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+PFJl

Y051bT4yPC9SZWNOdW0+PElEVGV4dD5HZW5ldGljIHRlc3RpbmcgaW4gdGhlIGVwaWxlcHNpZXMt

LXJlcG9ydCBvZiB0aGUgSUxBRSBHZW5ldGljcyBDb21taXNzaW9uPC9JRFRleHQ+PE1ETCBSZWZf

VHlwZT0iSm91cm5hbCI+PFJlZl9UeXBlPkpvdXJuYWw8L1JlZl9UeXBlPjxSZWZfSUQ+MjwvUmVm

X0lEPjxUaXRsZV9QcmltYXJ5PkdlbmV0aWMgdGVzdGluZyBpbiB0aGUgZXBpbGVwc2llcy0tcmVw

b3J0IG9mIHRoZSBJTEFFIEdlbmV0aWNzIENvbW1pc3Npb248L1RpdGxlX1ByaW1hcnk+PEF1dGhv

cnNfUHJpbWFyeT5PdHRtYW4sUi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pkhp

cm9zZSxTLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+SmFpbixTLjwvQXV0aG9y

c19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+TGVyY2hlLEguPC9BdXRob3JzX1ByaW1hcnk+PEF1

dGhvcnNfUHJpbWFyeT5Mb3Blcy1DZW5kZXMsSS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19Q

cmltYXJ5Pk5vZWJlbHMsSi5MLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U2Vy

cmF0b3NhLEouPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5aYXJhLEYuPC9BdXRo

b3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5TY2hlZmZlcixJLkUuPC9BdXRob3JzX1ByaW1h

cnk+PERhdGVfUHJpbWFyeT4yMDEwLzQ8L0RhdGVfUHJpbWFyeT48S2V5d29yZHM+QWRvbGVzY2Vu

dDwvS2V5d29yZHM+PEtleXdvcmRzPkFnZSBvZiBPbnNldDwvS2V5d29yZHM+PEtleXdvcmRzPkNo

aWxkPC9LZXl3b3Jkcz48S2V5d29yZHM+Q2hpbGQsUHJlc2Nob29sPC9LZXl3b3Jkcz48S2V5d29y

ZHM+Q2hyb21vc29tZSBNYXBwaW5nPC9LZXl3b3Jkcz48S2V5d29yZHM+ZGlhZ25vc2lzPC9LZXl3

b3Jkcz48S2V5d29yZHM+RE5BIE11dGF0aW9uYWwgQW5hbHlzaXM8L0tleXdvcmRzPjxLZXl3b3Jk

cz5FcGlsZXBzeTwvS2V5d29yZHM+PEtleXdvcmRzPmV0aGljczwvS2V5d29yZHM+PEtleXdvcmRz

PkV0aGljcyxNZWRpY2FsPC9LZXl3b3Jkcz48S2V5d29yZHM+RmVtYWxlPC9LZXl3b3Jkcz48S2V5

d29yZHM+R2VuZXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5HZW5ldGljIFByZWRpc3Bvc2l0aW9uIHRv

IERpc2Vhc2U8L0tleXdvcmRzPjxLZXl3b3Jkcz5HZW5ldGljIFRlc3Rpbmc8L0tleXdvcmRzPjxL

ZXl3b3Jkcz5nZW5ldGljczwvS2V5d29yZHM+PEtleXdvcmRzPkh1bWFuczwvS2V5d29yZHM+PEtl

eXdvcmRzPkluZmFudDwvS2V5d29yZHM+PEtleXdvcmRzPkluZmFudCxOZXdib3JuPC9LZXl3b3Jk

cz48S2V5d29yZHM+TWFsZTwvS2V5d29yZHM+PEtleXdvcmRzPlByZWRpY3RpdmUgVmFsdWUgb2Yg

VGVzdHM8L0tleXdvcmRzPjxLZXl3b3Jkcz5Qcm9nbm9zaXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5T

cGFzbXMsSW5mYW50aWxlPC9LZXl3b3Jkcz48S2V5d29yZHM+U3luZHJvbWU8L0tleXdvcmRzPjxL

ZXl3b3Jkcz5Zb3VuZyBBZHVsdDwvS2V5d29yZHM+PFJlcHJpbnQ+Tm90IGluIEZpbGU8L1JlcHJp

bnQ+PFN0YXJ0X1BhZ2U+NjU1PC9TdGFydF9QYWdlPjxFbmRfUGFnZT42NzA8L0VuZF9QYWdlPjxQ

ZXJpb2RpY2FsPkVwaWxlcHNpYTwvUGVyaW9kaWNhbD48Vm9sdW1lPjUxPC9Wb2x1bWU+PElzc3Vl

PjQ8L0lzc3VlPjxVc2VyX0RlZl81PlBNQzI4NTU3ODQ8L1VzZXJfRGVmXzU+PE1pc2NfMz5FUEky

NDI5IFtwaWldOzEwLjExMTEvai4xNTI4LTExNjcuMjAwOS4wMjQyOS54IFtkb2ldPC9NaXNjXzM+

PEFkZHJlc3M+Ry4gSC4gU2VyZ2lldnNreSBDZW50ZXIgYW5kIERlcGFydG1lbnQgb2YgRXBpZGVt

aW9sb2d5LCBDb2x1bWJpYSBVbml2ZXJzaXR5LCBOZXcgWW9yaywgTlksIFVTQS4gcm82QGNvbHVt

YmlhLmVkdTwvQWRkcmVzcz48V2ViX1VSTD5QTToyMDEwMDIyNTwvV2ViX1VSTD48WlpfSm91cm5h

bFN0ZEFiYnJldj48ZiBuYW1lPSJTeXN0ZW0iPkVwaWxlcHNpYTwvZj48L1paX0pvdXJuYWxTdGRB

YmJyZXY+PFpaX1dvcmtmb3JtSUQ+MTwvWlpfV29ya2Zvcm1JRD48L01ETD48L0NpdGU+PC9SZWZt

YW4+

ADDIN REFMGR.CITE PFJlZm1hbj48Q2l0ZT48QXV0aG9yPk90dG1hbjwvQXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+PFJl

Y051bT4yPC9SZWNOdW0+PElEVGV4dD5HZW5ldGljIHRlc3RpbmcgaW4gdGhlIGVwaWxlcHNpZXMt

LXJlcG9ydCBvZiB0aGUgSUxBRSBHZW5ldGljcyBDb21taXNzaW9uPC9JRFRleHQ+PE1ETCBSZWZf

VHlwZT0iSm91cm5hbCI+PFJlZl9UeXBlPkpvdXJuYWw8L1JlZl9UeXBlPjxSZWZfSUQ+MjwvUmVm

X0lEPjxUaXRsZV9QcmltYXJ5PkdlbmV0aWMgdGVzdGluZyBpbiB0aGUgZXBpbGVwc2llcy0tcmVw

b3J0IG9mIHRoZSBJTEFFIEdlbmV0aWNzIENvbW1pc3Npb248L1RpdGxlX1ByaW1hcnk+PEF1dGhv

cnNfUHJpbWFyeT5PdHRtYW4sUi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pkhp

cm9zZSxTLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+SmFpbixTLjwvQXV0aG9y

c19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+TGVyY2hlLEguPC9BdXRob3JzX1ByaW1hcnk+PEF1

dGhvcnNfUHJpbWFyeT5Mb3Blcy1DZW5kZXMsSS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19Q

cmltYXJ5Pk5vZWJlbHMsSi5MLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U2Vy

cmF0b3NhLEouPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5aYXJhLEYuPC9BdXRo

b3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5TY2hlZmZlcixJLkUuPC9BdXRob3JzX1ByaW1h

cnk+PERhdGVfUHJpbWFyeT4yMDEwLzQ8L0RhdGVfUHJpbWFyeT48S2V5d29yZHM+QWRvbGVzY2Vu

dDwvS2V5d29yZHM+PEtleXdvcmRzPkFnZSBvZiBPbnNldDwvS2V5d29yZHM+PEtleXdvcmRzPkNo

aWxkPC9LZXl3b3Jkcz48S2V5d29yZHM+Q2hpbGQsUHJlc2Nob29sPC9LZXl3b3Jkcz48S2V5d29y

ZHM+Q2hyb21vc29tZSBNYXBwaW5nPC9LZXl3b3Jkcz48S2V5d29yZHM+ZGlhZ25vc2lzPC9LZXl3

b3Jkcz48S2V5d29yZHM+RE5BIE11dGF0aW9uYWwgQW5hbHlzaXM8L0tleXdvcmRzPjxLZXl3b3Jk

cz5FcGlsZXBzeTwvS2V5d29yZHM+PEtleXdvcmRzPmV0aGljczwvS2V5d29yZHM+PEtleXdvcmRz

PkV0aGljcyxNZWRpY2FsPC9LZXl3b3Jkcz48S2V5d29yZHM+RmVtYWxlPC9LZXl3b3Jkcz48S2V5

d29yZHM+R2VuZXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5HZW5ldGljIFByZWRpc3Bvc2l0aW9uIHRv

IERpc2Vhc2U8L0tleXdvcmRzPjxLZXl3b3Jkcz5HZW5ldGljIFRlc3Rpbmc8L0tleXdvcmRzPjxL

ZXl3b3Jkcz5nZW5ldGljczwvS2V5d29yZHM+PEtleXdvcmRzPkh1bWFuczwvS2V5d29yZHM+PEtl

eXdvcmRzPkluZmFudDwvS2V5d29yZHM+PEtleXdvcmRzPkluZmFudCxOZXdib3JuPC9LZXl3b3Jk

cz48S2V5d29yZHM+TWFsZTwvS2V5d29yZHM+PEtleXdvcmRzPlByZWRpY3RpdmUgVmFsdWUgb2Yg

VGVzdHM8L0tleXdvcmRzPjxLZXl3b3Jkcz5Qcm9nbm9zaXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5T

cGFzbXMsSW5mYW50aWxlPC9LZXl3b3Jkcz48S2V5d29yZHM+U3luZHJvbWU8L0tleXdvcmRzPjxL

ZXl3b3Jkcz5Zb3VuZyBBZHVsdDwvS2V5d29yZHM+PFJlcHJpbnQ+Tm90IGluIEZpbGU8L1JlcHJp

bnQ+PFN0YXJ0X1BhZ2U+NjU1PC9TdGFydF9QYWdlPjxFbmRfUGFnZT42NzA8L0VuZF9QYWdlPjxQ

ZXJpb2RpY2FsPkVwaWxlcHNpYTwvUGVyaW9kaWNhbD48Vm9sdW1lPjUxPC9Wb2x1bWU+PElzc3Vl

PjQ8L0lzc3VlPjxVc2VyX0RlZl81PlBNQzI4NTU3ODQ8L1VzZXJfRGVmXzU+PE1pc2NfMz5FUEky

NDI5IFtwaWldOzEwLjExMTEvai4xNTI4LTExNjcuMjAwOS4wMjQyOS54IFtkb2ldPC9NaXNjXzM+

PEFkZHJlc3M+Ry4gSC4gU2VyZ2lldnNreSBDZW50ZXIgYW5kIERlcGFydG1lbnQgb2YgRXBpZGVt

aW9sb2d5LCBDb2x1bWJpYSBVbml2ZXJzaXR5LCBOZXcgWW9yaywgTlksIFVTQS4gcm82QGNvbHVt

YmlhLmVkdTwvQWRkcmVzcz48V2ViX1VSTD5QTToyMDEwMDIyNTwvV2ViX1VSTD48WlpfSm91cm5h

bFN0ZEFiYnJldj48ZiBuYW1lPSJTeXN0ZW0iPkVwaWxlcHNpYTwvZj48L1paX0pvdXJuYWxTdGRB

YmJyZXY+PFpaX1dvcmtmb3JtSUQ+MTwvWlpfV29ya2Zvcm1JRD48L01ETD48L0NpdGU+PC9SZWZt

YW4+

ADDIN EN.CITE.DATA 1 These types include early-onset spasms, X-linked infantile spasms, Dravet and related syndromes, Ohtahara syndrome, epilepsy and mental retardation limited to females (now known as PCDH19 female-limited epilepsy), early-onset absence epilepsy, autosomal dominant nocturnal frontal lobe epilepsy, and epilepsy with paroxysmal exercise-induced dyskinesia. Distinction between the phenotypic subgroups provides helpful information for prognostic and genetic counseling and clinical care. Epilepsy is a highly heterogeneous genetic disorder, meaning many genes have been associated with epilepsy. For example, mutations in genes encoding ion channels, proteins associated to the vesical synaptic cycle or proteins involved in energy metabolism are known to cause epilepsy. The large number of genes associated with epilepsy complicates the genetic diagnosis.-How will the results of the genetic test, whether negative or positive, impact the future management of the member being tested? (explain all that apply):Stop the need for further diagnostic testing: As the NGS assay covers multiple relevant genes using a single blood draw, it can potentially help avoid a long series of laborious, costly, and stressful diagnostic procedures. Inform on prognosis:Change treatment plan (e.g. medical or surgical decision-making or treatment): Depending on the specific mutations identified, test results could help guide antiepileptic pharmacotherapy in some cases. For example, administration of sodium channel blockers would be avoided in patients with Dravet syndrome harboring an SCN1A mutation, while detection of an ALDH7A1 mutation might suggest responsiveness to pyridoxine (depending on other clinical features).PFJlZm1hbj48Q2l0ZT48QXV0aG9yPk1pbGxzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48UmVj

TnVtPjEyNDwvUmVjTnVtPjxJRFRleHQ+R2Vub3R5cGljIGFuZCBwaGVub3R5cGljIHNwZWN0cnVt

IG9mIHB5cmlkb3hpbmUtZGVwZW5kZW50IGVwaWxlcHN5IChBTERIN0ExIGRlZmljaWVuY3kpPC9J

RFRleHQ+PE1ETCBSZWZfVHlwZT0iSm91cm5hbCI+PFJlZl9UeXBlPkpvdXJuYWw8L1JlZl9UeXBl

PjxSZWZfSUQ+MTI0PC9SZWZfSUQ+PFRpdGxlX1ByaW1hcnk+R2Vub3R5cGljIGFuZCBwaGVub3R5

cGljIHNwZWN0cnVtIG9mIHB5cmlkb3hpbmUtZGVwZW5kZW50IGVwaWxlcHN5ICg8aT5BTERIN0Ex

PC9pPiBkZWZpY2llbmN5KTwvVGl0bGVfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pk1pbGxzLFAu

Qi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkZvb3RpdHQsRS5KLjwvQXV0aG9y

c19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+TWlsbHMsSy5BLjwvQXV0aG9yc19QcmltYXJ5PjxB

dXRob3JzX1ByaW1hcnk+VHVzY2hsLEsuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFy

eT5BeWxldHQsUy48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlZhcmFka2FyLFMu

PC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5IZW1pbmd3YXksQy48L0F1dGhvcnNf

UHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pk1hcmxvdyxOLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRo

b3JzX1ByaW1hcnk+UmVubmllLEouPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5C

YXh0ZXIsUC48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkR1bGFjLE8uPC9BdXRo

b3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5OYWJib3V0LFIuPC9BdXRob3JzX1ByaW1hcnk+

PEF1dGhvcnNfUHJpbWFyeT5DcmFpZ2VuLFcuSi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19Q

cmltYXJ5PlNjaG1pdHQsQi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkZlaWxs

ZXQsRi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkNocmlzdGVuc2VuLEUuPC9B

dXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5EZSxMb25sYXkgUC48L0F1dGhvcnNfUHJp

bWFyeT48QXV0aG9yc19QcmltYXJ5PlBpa2UsTS5HLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3Jz

X1ByaW1hcnk+SHVnaGVzLE0uSS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlN0

cnV5cyxFLkEuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5KYWtvYnMsQy48L0F1

dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Plp1YmVyaSxTLk0uPC9BdXRob3JzX1ByaW1h

cnk+PEF1dGhvcnNfUHJpbWFyeT5DbGF5dG9uLFAuVC48L0F1dGhvcnNfUHJpbWFyeT48RGF0ZV9Q

cmltYXJ5PjIwMTAvNzwvRGF0ZV9QcmltYXJ5PjxLZXl3b3Jkcz4yLUFtaW5vYWRpcGljIEFjaWQ8

L0tleXdvcmRzPjxLZXl3b3Jkcz5hYm5vcm1hbGl0aWVzPC9LZXl3b3Jkcz48S2V5d29yZHM+QWxk

ZWh5ZGUgRGVoeWRyb2dlbmFzZTwvS2V5d29yZHM+PEtleXdvcmRzPmFuYWxvZ3MgJmFtcDsgZGVy

aXZhdGl2ZXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5CaW9sb2dpY2FsIE1hcmtlcnM8L0tleXdvcmRz

PjxLZXl3b3Jkcz5CcmFpbjwvS2V5d29yZHM+PEtleXdvcmRzPkNoaWxkPC9LZXl3b3Jkcz48S2V5

d29yZHM+ZGVmaWNpZW5jeTwvS2V5d29yZHM+PEtleXdvcmRzPmRpYWdub3NpczwvS2V5d29yZHM+

PEtleXdvcmRzPkRuYTwvS2V5d29yZHM+PEtleXdvcmRzPmRydWcgdGhlcmFweTwvS2V5d29yZHM+

PEtleXdvcmRzPkVsZWN0cm9lbmNlcGhhbG9ncmFwaHk8L0tleXdvcmRzPjxLZXl3b3Jkcz5FcGls

ZXBzeTwvS2V5d29yZHM+PEtleXdvcmRzPkZlbWFsZTwvS2V5d29yZHM+PEtleXdvcmRzPmdlbmV0

aWNzPC9LZXl3b3Jkcz48S2V5d29yZHM+R2Vub3R5cGU8L0tleXdvcmRzPjxLZXl3b3Jkcz5IdW1h

bnM8L0tleXdvcmRzPjxLZXl3b3Jkcz5JbmZhbnQ8L0tleXdvcmRzPjxLZXl3b3Jkcz5NYWduZXRp

YyBSZXNvbmFuY2UgSW1hZ2luZzwvS2V5d29yZHM+PEtleXdvcmRzPk1hbGU8L0tleXdvcmRzPjxL

ZXl3b3Jkcz5NdXRhdGlvbjwvS2V5d29yZHM+PEtleXdvcmRzPk11dGF0aW9uLE1pc3NlbnNlPC9L

ZXl3b3Jkcz48S2V5d29yZHM+cGF0aG9sb2d5PC9LZXl3b3Jkcz48S2V5d29yZHM+UGhlbm90eXBl

PC9LZXl3b3Jkcz48S2V5d29yZHM+UHlyaWRveGluZTwvS2V5d29yZHM+PEtleXdvcmRzPlNlaXp1

cmVzPC9LZXl3b3Jkcz48S2V5d29yZHM+dGhlcmFwZXV0aWMgdXNlPC9LZXl3b3Jkcz48S2V5d29y

ZHM+dXJpbmU8L0tleXdvcmRzPjxSZXByaW50Pk5vdCBpbiBGaWxlPC9SZXByaW50PjxTdGFydF9Q

YWdlPjIxNDg8L1N0YXJ0X1BhZ2U+PEVuZF9QYWdlPjIxNTk8L0VuZF9QYWdlPjxQZXJpb2RpY2Fs

PkJyYWluPC9QZXJpb2RpY2FsPjxWb2x1bWU+MTMzPC9Wb2x1bWU+PElzc3VlPlB0IDc8L0lzc3Vl

PjxVc2VyX0RlZl81PlBNQzI4OTI5NDU8L1VzZXJfRGVmXzU+PE1pc2NfMz5hd3ExNDMgW3BpaV07

MTAuMTA5My9icmFpbi9hd3ExNDMgW2RvaV08L01pc2NfMz48QWRkcmVzcz5JbnN0aXR1dGUgb2Yg

Q2hpbGQgSGVhbHRoLCBVbml2ZXJzaXR5IENvbGxlZ2UgTG9uZG9uIHdpdGggR3JlYXQgT3Jtb25k

IFN0cmVldCBIb3NwaXRhbCBmb3IgQ2hpbGRyZW4sIE5hdGlvbmFsIEhlYWx0aCBTZXJ2aWNlIFRy

dXN0LCBMb25kb24sIFVLPC9BZGRyZXNzPjxXZWJfVVJMPlBNOjIwNTU0NjU5PC9XZWJfVVJMPjxa

Wl9Kb3VybmFsU3RkQWJicmV2PjxmIG5hbWU9IlN5c3RlbSI+QnJhaW48L2Y+PC9aWl9Kb3VybmFs

U3RkQWJicmV2PjxaWl9Xb3JrZm9ybUlEPjE8L1paX1dvcmtmb3JtSUQ+PC9NREw+PC9DaXRlPjwv

UmVmbWFuPm==

ADDIN REFMGR.CITE PFJlZm1hbj48Q2l0ZT48QXV0aG9yPk1pbGxzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48UmVj

TnVtPjEyNDwvUmVjTnVtPjxJRFRleHQ+R2Vub3R5cGljIGFuZCBwaGVub3R5cGljIHNwZWN0cnVt

IG9mIHB5cmlkb3hpbmUtZGVwZW5kZW50IGVwaWxlcHN5IChBTERIN0ExIGRlZmljaWVuY3kpPC9J

RFRleHQ+PE1ETCBSZWZfVHlwZT0iSm91cm5hbCI+PFJlZl9UeXBlPkpvdXJuYWw8L1JlZl9UeXBl

PjxSZWZfSUQ+MTI0PC9SZWZfSUQ+PFRpdGxlX1ByaW1hcnk+R2Vub3R5cGljIGFuZCBwaGVub3R5

cGljIHNwZWN0cnVtIG9mIHB5cmlkb3hpbmUtZGVwZW5kZW50IGVwaWxlcHN5ICg8aT5BTERIN0Ex

PC9pPiBkZWZpY2llbmN5KTwvVGl0bGVfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pk1pbGxzLFAu

Qi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkZvb3RpdHQsRS5KLjwvQXV0aG9y

c19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+TWlsbHMsSy5BLjwvQXV0aG9yc19QcmltYXJ5PjxB

dXRob3JzX1ByaW1hcnk+VHVzY2hsLEsuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFy

eT5BeWxldHQsUy48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlZhcmFka2FyLFMu

PC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5IZW1pbmd3YXksQy48L0F1dGhvcnNf

UHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pk1hcmxvdyxOLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRo

b3JzX1ByaW1hcnk+UmVubmllLEouPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5C

YXh0ZXIsUC48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkR1bGFjLE8uPC9BdXRo

b3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5OYWJib3V0LFIuPC9BdXRob3JzX1ByaW1hcnk+

PEF1dGhvcnNfUHJpbWFyeT5DcmFpZ2VuLFcuSi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19Q

cmltYXJ5PlNjaG1pdHQsQi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkZlaWxs

ZXQsRi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkNocmlzdGVuc2VuLEUuPC9B

dXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5EZSxMb25sYXkgUC48L0F1dGhvcnNfUHJp

bWFyeT48QXV0aG9yc19QcmltYXJ5PlBpa2UsTS5HLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3Jz

X1ByaW1hcnk+SHVnaGVzLE0uSS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlN0

cnV5cyxFLkEuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5KYWtvYnMsQy48L0F1

dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Plp1YmVyaSxTLk0uPC9BdXRob3JzX1ByaW1h

cnk+PEF1dGhvcnNfUHJpbWFyeT5DbGF5dG9uLFAuVC48L0F1dGhvcnNfUHJpbWFyeT48RGF0ZV9Q

cmltYXJ5PjIwMTAvNzwvRGF0ZV9QcmltYXJ5PjxLZXl3b3Jkcz4yLUFtaW5vYWRpcGljIEFjaWQ8

L0tleXdvcmRzPjxLZXl3b3Jkcz5hYm5vcm1hbGl0aWVzPC9LZXl3b3Jkcz48S2V5d29yZHM+QWxk

ZWh5ZGUgRGVoeWRyb2dlbmFzZTwvS2V5d29yZHM+PEtleXdvcmRzPmFuYWxvZ3MgJmFtcDsgZGVy

aXZhdGl2ZXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5CaW9sb2dpY2FsIE1hcmtlcnM8L0tleXdvcmRz

PjxLZXl3b3Jkcz5CcmFpbjwvS2V5d29yZHM+PEtleXdvcmRzPkNoaWxkPC9LZXl3b3Jkcz48S2V5

d29yZHM+ZGVmaWNpZW5jeTwvS2V5d29yZHM+PEtleXdvcmRzPmRpYWdub3NpczwvS2V5d29yZHM+

PEtleXdvcmRzPkRuYTwvS2V5d29yZHM+PEtleXdvcmRzPmRydWcgdGhlcmFweTwvS2V5d29yZHM+

PEtleXdvcmRzPkVsZWN0cm9lbmNlcGhhbG9ncmFwaHk8L0tleXdvcmRzPjxLZXl3b3Jkcz5FcGls

ZXBzeTwvS2V5d29yZHM+PEtleXdvcmRzPkZlbWFsZTwvS2V5d29yZHM+PEtleXdvcmRzPmdlbmV0

aWNzPC9LZXl3b3Jkcz48S2V5d29yZHM+R2Vub3R5cGU8L0tleXdvcmRzPjxLZXl3b3Jkcz5IdW1h

bnM8L0tleXdvcmRzPjxLZXl3b3Jkcz5JbmZhbnQ8L0tleXdvcmRzPjxLZXl3b3Jkcz5NYWduZXRp

YyBSZXNvbmFuY2UgSW1hZ2luZzwvS2V5d29yZHM+PEtleXdvcmRzPk1hbGU8L0tleXdvcmRzPjxL

ZXl3b3Jkcz5NdXRhdGlvbjwvS2V5d29yZHM+PEtleXdvcmRzPk11dGF0aW9uLE1pc3NlbnNlPC9L

ZXl3b3Jkcz48S2V5d29yZHM+cGF0aG9sb2d5PC9LZXl3b3Jkcz48S2V5d29yZHM+UGhlbm90eXBl

PC9LZXl3b3Jkcz48S2V5d29yZHM+UHlyaWRveGluZTwvS2V5d29yZHM+PEtleXdvcmRzPlNlaXp1

cmVzPC9LZXl3b3Jkcz48S2V5d29yZHM+dGhlcmFwZXV0aWMgdXNlPC9LZXl3b3Jkcz48S2V5d29y

ZHM+dXJpbmU8L0tleXdvcmRzPjxSZXByaW50Pk5vdCBpbiBGaWxlPC9SZXByaW50PjxTdGFydF9Q

YWdlPjIxNDg8L1N0YXJ0X1BhZ2U+PEVuZF9QYWdlPjIxNTk8L0VuZF9QYWdlPjxQZXJpb2RpY2Fs

PkJyYWluPC9QZXJpb2RpY2FsPjxWb2x1bWU+MTMzPC9Wb2x1bWU+PElzc3VlPlB0IDc8L0lzc3Vl

PjxVc2VyX0RlZl81PlBNQzI4OTI5NDU8L1VzZXJfRGVmXzU+PE1pc2NfMz5hd3ExNDMgW3BpaV07

MTAuMTA5My9icmFpbi9hd3ExNDMgW2RvaV08L01pc2NfMz48QWRkcmVzcz5JbnN0aXR1dGUgb2Yg

Q2hpbGQgSGVhbHRoLCBVbml2ZXJzaXR5IENvbGxlZ2UgTG9uZG9uIHdpdGggR3JlYXQgT3Jtb25k

IFN0cmVldCBIb3NwaXRhbCBmb3IgQ2hpbGRyZW4sIE5hdGlvbmFsIEhlYWx0aCBTZXJ2aWNlIFRy

dXN0LCBMb25kb24sIFVLPC9BZGRyZXNzPjxXZWJfVVJMPlBNOjIwNTU0NjU5PC9XZWJfVVJMPjxa

Wl9Kb3VybmFsU3RkQWJicmV2PjxmIG5hbWU9IlN5c3RlbSI+QnJhaW48L2Y+PC9aWl9Kb3VybmFs

U3RkQWJicmV2PjxaWl9Xb3JrZm9ybUlEPjE8L1paX1dvcmtmb3JtSUQ+PC9NREw+PC9DaXRlPjwv

UmVmbWFuPm==

ADDIN EN.CITE.DATA 7Change surveillance (e.g. annual echocardiograms, either begin or stop): The following surveillance may be required: EEG, neuropsychological evaluation, hearing evaluation, developmental assessment, speech/language evaluation,Provide information for family members: Inherited epilepsy disorders can occur in several inheritance patterns, including autosomal dominant, autosomal recessive, and X-linked dominant. Identification of a causal mutation will allow for accurate recurrence risk counseling.-What is the probability that this test will be positive? If this is not known, then please indicate which clinical features increase the probability that this test will provide a diagnosis. The large number of genes with putative links to epilepsy complicates the identification of an underlying genetic. Next-generation sequencing (NGS) allows sequencing of numerous genes simultaneously. NGS panels are appropriate and more cost effective for detecting mutations in disorders with a highly heterogeneous genetic background, such as epilepsy.PFJlZm1hbj48Q2l0ZT48QXV0aG9yPkxlbWtlPC9BdXRob3I+PFllYXI+MjAxMjwvWWVhcj48UmVj

TnVtPjg8L1JlY051bT48SURUZXh0PlRhcmdldGVkIG5leHQgZ2VuZXJhdGlvbiBzZXF1ZW5jaW5n

IGFzIGEgZGlhZ25vc3RpYyB0b29sIGluIGVwaWxlcHRpYyBkaXNvcmRlcnM8L0lEVGV4dD48TURM

IFJlZl9UeXBlPSJKb3VybmFsIj48UmVmX1R5cGU+Sm91cm5hbDwvUmVmX1R5cGU+PFJlZl9JRD44

PC9SZWZfSUQ+PFRpdGxlX1ByaW1hcnk+VGFyZ2V0ZWQgbmV4dCBnZW5lcmF0aW9uIHNlcXVlbmNp

bmcgYXMgYSBkaWFnbm9zdGljIHRvb2wgaW4gZXBpbGVwdGljIGRpc29yZGVyczwvVGl0bGVfUHJp

bWFyeT48QXV0aG9yc19QcmltYXJ5PkxlbWtlLEouUi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9y

c19QcmltYXJ5PlJpZXNjaCxFLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U2No

ZXVyZW5icmFuZCxULjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U2NodWJhY2gs

TS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PldpbGhlbG0sQy48L0F1dGhvcnNf

UHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlN0ZWluZXIsSS48L0F1dGhvcnNfUHJpbWFyeT48QXV0

aG9yc19QcmltYXJ5PkhhbnNlbixKLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+

Q291cmFnZSxDLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+R2FsbGF0aSxTLjwv

QXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+QnVya2ksUy48L0F1dGhvcnNfUHJpbWFy

eT48QXV0aG9yc19QcmltYXJ5PlN0cm96emksUy48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19Q

cmltYXJ5PlNpbW9uZXR0aSxCLkcuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5H

cnVudCxTLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U3RlaW5saW4sTS48L0F1

dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkFsYmVyLE0uPC9BdXRob3JzX1ByaW1hcnk+

PEF1dGhvcnNfUHJpbWFyeT5Xb2xmZixNLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1h

cnk+S2xvcHN0b2NrLFQuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5Qcm90dCxF

LkMuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5Mb3JlbnosUi48L0F1dGhvcnNf

UHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlNwYWljaCxDLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRo

b3JzX1ByaW1hcnk+Um9uYSxTLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+TGFr

c2htaW5hcmFzaW1oYW4sTS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pktyb2xs

LEouPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5Eb3JuLFQuPC9BdXRob3JzX1By

aW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5LcmFtZXIsRy48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9y

c19QcmltYXJ5PlN5bm9memlrLE0uPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5C

ZWNrZXIsRi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PldlYmVyLFkuRy48L0F1

dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkxlcmNoZSxILjwvQXV0aG9yc19QcmltYXJ5

PjxBdXRob3JzX1ByaW1hcnk+Qm9obSxELjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1h

cnk+Qmlza3VwLFMuPC9BdXRob3JzX1ByaW1hcnk+PERhdGVfUHJpbWFyeT4yMDEyLzg8L0RhdGVf

UHJpbWFyeT48S2V5d29yZHM+QWRvbGVzY2VudDwvS2V5d29yZHM+PEtleXdvcmRzPkFkdWx0PC9L

ZXl3b3Jkcz48S2V5d29yZHM+Q2hpbGQ8L0tleXdvcmRzPjxLZXl3b3Jkcz5DaGlsZCxQcmVzY2hv

b2w8L0tleXdvcmRzPjxLZXl3b3Jkcz5kaWFnbm9zaXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5FcGls

ZXBzeTwvS2V5d29yZHM+PEtleXdvcmRzPkZlbWFsZTwvS2V5d29yZHM+PEtleXdvcmRzPkdlbmVz

PC9LZXl3b3Jkcz48S2V5d29yZHM+R2VuZXRpYyBQcmVkaXNwb3NpdGlvbiB0byBEaXNlYXNlPC9L

ZXl3b3Jkcz48S2V5d29yZHM+Z2VuZXRpY3M8L0tleXdvcmRzPjxLZXl3b3Jkcz5HZW5vdHlwZTwv

S2V5d29yZHM+PEtleXdvcmRzPkh1bWFuczwvS2V5d29yZHM+PEtleXdvcmRzPk1hbGU8L0tleXdv

cmRzPjxLZXl3b3Jkcz5NdXRhdGlvbjwvS2V5d29yZHM+PEtleXdvcmRzPlBoZW5vdHlwZTwvS2V5

d29yZHM+PEtleXdvcmRzPlNlcXVlbmNlIEFuYWx5c2lzLEROQTwvS2V5d29yZHM+PEtleXdvcmRz

PllvdW5nIEFkdWx0PC9LZXl3b3Jkcz48UmVwcmludD5Ob3QgaW4gRmlsZTwvUmVwcmludD48U3Rh

cnRfUGFnZT4xMzg3PC9TdGFydF9QYWdlPjxFbmRfUGFnZT4xMzk4PC9FbmRfUGFnZT48UGVyaW9k

aWNhbD5FcGlsZXBzaWE8L1BlcmlvZGljYWw+PFZvbHVtZT41MzwvVm9sdW1lPjxJc3N1ZT44PC9J

c3N1ZT48TWlzY18zPjEwLjExMTEvai4xNTI4LTExNjcuMjAxMi4wMzUxNi54IFtkb2ldPC9NaXNj

XzM+PEFkZHJlc3M+RGl2aXNpb24gb2YgSHVtYW4gR2VuZXRpY3MsIFVuaXZlcnNpdHkgQ2hpbGRy

ZW4mYXBvcztzIEhvc3BpdGFsIEluc2Vsc3BpdGFsLCBCZXJuLCBTd2l0emVybGFuZC4gam9oYW5u

ZXMubGVta2VAaW5zZWwuY2g8L0FkZHJlc3M+PFdlYl9VUkw+UE06MjI2MTIyNTc8L1dlYl9VUkw+

PFpaX0pvdXJuYWxTdGRBYmJyZXY+PGYgbmFtZT0iU3lzdGVtIj5FcGlsZXBzaWE8L2Y+PC9aWl9K

b3VybmFsU3RkQWJicmV2PjxaWl9Xb3JrZm9ybUlEPjE8L1paX1dvcmtmb3JtSUQ+PC9NREw+PC9D

aXRlPjwvUmVmbWFuPm==

ADDIN REFMGR.CITE PFJlZm1hbj48Q2l0ZT48QXV0aG9yPkxlbWtlPC9BdXRob3I+PFllYXI+MjAxMjwvWWVhcj48UmVj

TnVtPjg8L1JlY051bT48SURUZXh0PlRhcmdldGVkIG5leHQgZ2VuZXJhdGlvbiBzZXF1ZW5jaW5n

IGFzIGEgZGlhZ25vc3RpYyB0b29sIGluIGVwaWxlcHRpYyBkaXNvcmRlcnM8L0lEVGV4dD48TURM

IFJlZl9UeXBlPSJKb3VybmFsIj48UmVmX1R5cGU+Sm91cm5hbDwvUmVmX1R5cGU+PFJlZl9JRD44

PC9SZWZfSUQ+PFRpdGxlX1ByaW1hcnk+VGFyZ2V0ZWQgbmV4dCBnZW5lcmF0aW9uIHNlcXVlbmNp

bmcgYXMgYSBkaWFnbm9zdGljIHRvb2wgaW4gZXBpbGVwdGljIGRpc29yZGVyczwvVGl0bGVfUHJp

bWFyeT48QXV0aG9yc19QcmltYXJ5PkxlbWtlLEouUi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9y

c19QcmltYXJ5PlJpZXNjaCxFLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U2No

ZXVyZW5icmFuZCxULjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U2NodWJhY2gs

TS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PldpbGhlbG0sQy48L0F1dGhvcnNf

UHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlN0ZWluZXIsSS48L0F1dGhvcnNfUHJpbWFyeT48QXV0

aG9yc19QcmltYXJ5PkhhbnNlbixKLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+

Q291cmFnZSxDLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+R2FsbGF0aSxTLjwv

QXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+QnVya2ksUy48L0F1dGhvcnNfUHJpbWFy

eT48QXV0aG9yc19QcmltYXJ5PlN0cm96emksUy48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19Q

cmltYXJ5PlNpbW9uZXR0aSxCLkcuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5H

cnVudCxTLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+U3RlaW5saW4sTS48L0F1

dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkFsYmVyLE0uPC9BdXRob3JzX1ByaW1hcnk+

PEF1dGhvcnNfUHJpbWFyeT5Xb2xmZixNLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1h

cnk+S2xvcHN0b2NrLFQuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5Qcm90dCxF

LkMuPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5Mb3JlbnosUi48L0F1dGhvcnNf

UHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PlNwYWljaCxDLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRo

b3JzX1ByaW1hcnk+Um9uYSxTLjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1hcnk+TGFr

c2htaW5hcmFzaW1oYW4sTS48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5Pktyb2xs

LEouPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5Eb3JuLFQuPC9BdXRob3JzX1By

aW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5LcmFtZXIsRy48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9y

c19QcmltYXJ5PlN5bm9memlrLE0uPC9BdXRob3JzX1ByaW1hcnk+PEF1dGhvcnNfUHJpbWFyeT5C

ZWNrZXIsRi48L0F1dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PldlYmVyLFkuRy48L0F1

dGhvcnNfUHJpbWFyeT48QXV0aG9yc19QcmltYXJ5PkxlcmNoZSxILjwvQXV0aG9yc19QcmltYXJ5

PjxBdXRob3JzX1ByaW1hcnk+Qm9obSxELjwvQXV0aG9yc19QcmltYXJ5PjxBdXRob3JzX1ByaW1h

cnk+Qmlza3VwLFMuPC9BdXRob3JzX1ByaW1hcnk+PERhdGVfUHJpbWFyeT4yMDEyLzg8L0RhdGVf

UHJpbWFyeT48S2V5d29yZHM+QWRvbGVzY2VudDwvS2V5d29yZHM+PEtleXdvcmRzPkFkdWx0PC9L

ZXl3b3Jkcz48S2V5d29yZHM+Q2hpbGQ8L0tleXdvcmRzPjxLZXl3b3Jkcz5DaGlsZCxQcmVzY2hv

b2w8L0tleXdvcmRzPjxLZXl3b3Jkcz5kaWFnbm9zaXM8L0tleXdvcmRzPjxLZXl3b3Jkcz5FcGls

ZXBzeTwvS2V5d29yZHM+PEtleXdvcmRzPkZlbWFsZTwvS2V5d29yZHM+PEtleXdvcmRzPkdlbmVz

PC9LZXl3b3Jkcz48S2V5d29yZHM+R2VuZXRpYyBQcmVkaXNwb3NpdGlvbiB0byBEaXNlYXNlPC9L

ZXl3b3Jkcz48S2V5d29yZHM+Z2VuZXRpY3M8L0tleXdvcmRzPjxLZXl3b3Jkcz5HZW5vdHlwZTwv

S2V5d29yZHM+PEtleXdvcmRzPkh1bWFuczwvS2V5d29yZHM+PEtleXdvcmRzPk1hbGU8L0tleXdv

cmRzPjxLZXl3b3Jkcz5NdXRhdGlvbjwvS2V5d29yZHM+PEtleXdvcmRzPlBoZW5vdHlwZTwvS2V5

d29yZHM+PEtleXdvcmRzPlNlcXVlbmNlIEFuYWx5c2lzLEROQTwvS2V5d29yZHM+PEtleXdvcmRz

PllvdW5nIEFkdWx0PC9LZXl3b3Jkcz48UmVwcmludD5Ob3QgaW4gRmlsZTwvUmVwcmludD48U3Rh

cnRfUGFnZT4xMzg3PC9TdGFydF9QYWdlPjxFbmRfUGFnZT4xMzk4PC9FbmRfUGFnZT48UGVyaW9k

aWNhbD5FcGlsZXBzaWE8L1BlcmlvZGljYWw+PFZvbHVtZT41MzwvVm9sdW1lPjxJc3N1ZT44PC9J

c3N1ZT48TWlzY18zPjEwLjExMTEvai4xNTI4LTExNjcuMjAxMi4wMzUxNi54IFtkb2ldPC9NaXNj

XzM+PEFkZHJlc3M+RGl2aXNpb24gb2YgSHVtYW4gR2VuZXRpY3MsIFVuaXZlcnNpdHkgQ2hpbGRy

ZW4mYXBvcztzIEhvc3BpdGFsIEluc2Vsc3BpdGFsLCBCZXJuLCBTd2l0emVybGFuZC4gam9oYW5u

ZXMubGVta2VAaW5zZWwuY2g8L0FkZHJlc3M+PFdlYl9VUkw+UE06MjI2MTIyNTc8L1dlYl9VUkw+

PFpaX0pvdXJuYWxTdGRBYmJyZXY+PGYgbmFtZT0iU3lzdGVtIj5FcGlsZXBzaWE8L2Y+PC9aWl9K

b3VybmFsU3RkQWJicmV2PjxaWl9Xb3JrZm9ybUlEPjE8L1paX1dvcmtmb3JtSUQ+PC9NREw+PC9D

aXRlPjwvUmVmbWFuPm==

ADDIN EN.CITE.DATA 4-If this is a request is for a gene panel, then please describe why a single gene test is not as useful. The clinical sensitivity of this test is dependent on the patient’s underlying genetic condition. For each condition, the table below shows the percentage of clinical cases in which a pathogenic variant is expected to be identified through analysis of the genes on this panel.Sensitivity by clinical conditionGenes71% of epileptic encephalopathy CHD2, CDKL5, KCNQ2, PCDH19, SCN1A, SCN2A, SYNGAP190% of benign familial epilepsy (KCNQ2, KCNQ3, PRRT2, SCN2A75% of Dravet syndrome PCDH19, SCN1A35% of Ohtahara syndrome STXBP120%–25% of autosomal dominant nocturnal frontal lobe epilepsy CHRNA2, CHRNA4, CHRNB2, DEPDC5, KCNT110% of early onset absence epilepsy and 90% of GLUT1 deficiency encephalopathy SLC2A1Unknown for rare subtypes of EIEEADSL, ALDH7A1, ALG13, ARHGEF9, ARX, ATP1A2, CACNA2D2, CLN3, CLN5, CLN6, CLN8, CSTB, CTSD, DNAJC5, EFHC1, EPM2A, FOLR1, GABRA1, GABRB3, GABRG2, GAMT, GATM, GNAO1, GOSR2, GRIN1, GRIN2A, GRIN2B, HCN1, HNRNPU, KCNH2, KCNJ10, KCTD7, LGI1, LIAS, MFSD8, NHLRC1, PLCB1, PNKP, PNPO, POLG, PPT1, PRICKLE1, QARS, RBFOX1, ROGDI, SCARB2, SCN1B, SCN3A, SCN5A, SCN9A, SLC25A22, SLC35A2, SLC6A8, SPTAN1, SYN1, TBC1D24, TPP1, TSC1, TSC2, WWOXRett/Atypical Rett syndromesMECP2: 95% of females with Rett syndrome cases and 75% of females with atypical Rett syndrome cases; CDKL5: 13% of atypical Rett syndrome cases; FOXG1: 1% of Rett syndrome cases; MBD5 and MEF2C are rare causes of Rett-like syndrome.Angelman/Angelman-like syndromes*UBE3A: 90% of Angelman syndrome cases; SLC9A6: 6% of Angelman syndrome cases; MBD5: Rare cause of Angelman-like syndrome (Christianson syndrome) cases); MECP2: Rare cause of Angelman-like syndrome cases.Pitt-Hopkins syndromeTCF4: 38% of Pitt-Hopkins syndrome cases.Mowat-Wilson syndrome**ZEB2: 98% of Mowat-Wilson syndrome cases.Koolen-DeVries syndrome (17q21.31 microdeletion syndrome)KANSL1: 100% of Koolen-DeVries syndrome cases.adenylosuccinate lyase deficiencyADSL: 100% of adenylosuccinate lyase deficiency cases alpha-thalassemia X-linked intellectual disability (ATRX) syndromeATRX: 100% of ATRX syndrome cases.Glass syndromeSATB2: 100% of Glass ?syndromesuccinic semialdehyde dehydrogenase (SSADH) deficiencyALDH5A1: 100% of SSADH deficiency cases. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download